Addex Therapeutics Management
Management criteria checks 2/4
Addex Therapeutics' CEO is Tim Dyer, appointed in Jan 2002, has a tenure of 22.67 years. directly owns 9.41% of the company’s shares, worth $794.04K. The average tenure of the management team and the board of directors is 7.5 years and 9.3 years respectively.
Key information
Tim Dyer
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 22.7yrs |
| CEO ownership | 9.4% |
| Management average tenure | 7.5yrs |
| Board average tenure | 9.3yrs |
Recent management updates
Recent updates
Addex, Indivior expand team up to develop therapies for substance use disorders
Aug 15Addex stock falls 11% amid $4.2M equity financing with Armistice
Jul 22Addex Therapeutics CEO Tim Dyer - Emerging Drugs For Central Nervous System (Video)
Oct 21Addex, Janssen initiate Phase 2 study of ADX71149 for epilepsy
Jun 07Addex Therapeutics reports Q1 results
May 05Addex drops 23% after pricing share offering
Jan 07Addex Therapeutics files to sell $10M of ADS
Dec 14Addex Therapeutics reports Q3 results
Nov 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -CHF 11m |
| Dec 31 2023 | n/a | n/a | -CHF 11m |
| Sep 30 2023 | n/a | n/a | -CHF 9m |
| Jun 30 2023 | n/a | n/a | -CHF 11m |
| Mar 31 2023 | n/a | n/a | -CHF 15m |
| Dec 31 2022 | n/a | n/a | -CHF 21m |
| Sep 30 2022 | n/a | n/a | -CHF 22m |
| Jun 30 2022 | n/a | n/a | -CHF 21m |
| Mar 31 2022 | n/a | n/a | -CHF 19m |
| Dec 31 2021 | n/a | n/a | -CHF 15m |
| Sep 30 2021 | n/a | n/a | -CHF 13m |
| Jun 30 2021 | n/a | n/a | -CHF 13m |
| Mar 31 2021 | n/a | n/a | -CHF 11m |
| Dec 31 2020 | CHF 917k | CHF 454k | -CHF 13m |
| Sep 30 2020 | n/a | n/a | -CHF 14m |
| Jun 30 2020 | n/a | n/a | -CHF 15m |
| Mar 31 2020 | n/a | n/a | -CHF 16m |
| Dec 31 2019 | CHF 709k | CHF 429k | -CHF 15m |
| Sep 30 2019 | n/a | n/a | -CHF 13m |
| Jun 30 2019 | n/a | n/a | -CHF 12m |
| Mar 31 2019 | n/a | n/a | -CHF 6m |
| Dec 31 2018 | CHF 2m | n/a | -CHF 2m |
Compensation vs Market: Insufficient data to establish whether Tim's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
CEO
Tim Dyer (56 yo)
22.7yrs
Tenure
Mr. Timothy Mark Dyer, also known as Tim, has been Chief Executive Officer at Addex Therapeutics Ltd. since June 1, 2013. Mr. Dyer co-founded Addex Therapeutics Ltd.(also known as Addex Pharmaceuticals Lt...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 22.7yrs | no data | 9.41% CHF 794.0k | |
| Chief Medical Officer & Director | 7.8yrs | no data | no data | |
| Head of Finance | 7.3yrs | no data | no data | |
| Head of Translational Science | 3.1yrs | no data | no data |
7.5yrs
Average Tenure
56.5yo
Average Age
Experienced Management: ADXN's management team is seasoned and experienced (7.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.7yrs | no data | 9.41% CHF 794.0k | |
| Chief Medical Officer & Director | 7.7yrs | no data | no data | |
| Independent Director | 6.3yrs | CHF 41.29k | no data | |
| Non-Executive Director | 9.3yrs | CHF 89.65k | 1.39% CHF 117.2k | |
| Independent Chairman of the Board | 15.4yrs | CHF 155.75k | 2.55% CHF 215.3k |
9.3yrs
Average Tenure
67yo
Average Age
Experienced Board: ADXN's board of directors are considered experienced (9.3 years average tenure).